237 related articles for article (PubMed ID: 22324953)
21. Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases.
Ramos-Casals M; Nardi N; Brito-Zerón P; Aguiló S; Gil V; Delgado G; Bové A; Font J
Semin Arthritis Rheum; 2006 Apr; 35(5):312-21. PubMed ID: 16616154
[TBL] [Abstract][Full Text] [Related]
22. Human scleroderma sera contain autoantibodies to protein components specific to the U3 small nucleolar RNP complex.
Yang JM; Hildebrandt B; Luderschmidt C; Pollard KM
Arthritis Rheum; 2003 Jan; 48(1):210-7. PubMed ID: 12528121
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary manifestations of scleroderma and mixed connective tissue disease.
Hant FN; Herpel LB; Silver RM
Clin Chest Med; 2010 Sep; 31(3):433-49. PubMed ID: 20692538
[TBL] [Abstract][Full Text] [Related]
24. Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer.
Igusa T; Hummers LK; Visvanathan K; Richardson C; Wigley FM; Casciola-Rosen L; Rosen A; Shah AA
Ann Rheum Dis; 2018 Aug; 77(8):1179-1186. PubMed ID: 29678941
[TBL] [Abstract][Full Text] [Related]
25. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis.
Jacobsen S; Ullman S; Shen GQ; Wiik A; Halberg P
J Rheumatol; 2001 Nov; 28(11):2454-9. PubMed ID: 11708418
[TBL] [Abstract][Full Text] [Related]
26. Clinical and serological heterogeneity in patients with anticentromere antibodies.
Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
[TBL] [Abstract][Full Text] [Related]
27. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis.
Cutolo M; Pizzorni C; Tuccio M; Burroni A; Craviotto C; Basso M; Seriolo B; Sulli A
Rheumatology (Oxford); 2004 Jun; 43(6):719-26. PubMed ID: 15026581
[TBL] [Abstract][Full Text] [Related]
28. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
[TBL] [Abstract][Full Text] [Related]
29. Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody.
Guillen-Del Castillo A; Pilar Simeón-Aznar C; Fonollosa-Pla V; Alonso-Vila S; Reverte-Vinaixa MM; Muñoz X; Pallisa E; Selva-O'allaghan A; Fernández-Codina A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2014 Dec; 44(3):331-7. PubMed ID: 25110305
[TBL] [Abstract][Full Text] [Related]
30. Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies.
Dugar M; Cox S; Limaye V; Blumbergs P; Roberts-Thomson PJ
Intern Med J; 2011 Sep; 41(9):674-9. PubMed ID: 20059602
[TBL] [Abstract][Full Text] [Related]
31. [Diagnostic significance of scleroderma and myositis-associated autoantibodies].
Genth E; Mierau R
Z Rheumatol; 1995; 54(1):39-49. PubMed ID: 7725809
[TBL] [Abstract][Full Text] [Related]
32. Serological profile of patients with systemic sclerosis.
Wielosz E; Dryglewska M; Majdan M
Postepy Hig Med Dosw (Online); 2014 Aug; 68():987-91. PubMed ID: 25228505
[TBL] [Abstract][Full Text] [Related]
33. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.
Walker UA; Tyndall A; Czirják L; Denton C; Farge-Bancel D; Kowal-Bielecka O; Müller-Ladner U; Bocelli-Tyndall C; Matucci-Cerinic M
Ann Rheum Dis; 2007 Jun; 66(6):754-63. PubMed ID: 17234652
[TBL] [Abstract][Full Text] [Related]
34. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
Mondini M; Vidali M; De Andrea M; Azzimonti B; Airò P; D'Ambrosio R; Riboldi P; Meroni PL; Albano E; Shoenfeld Y; Gariglio M; Landolfo S
Arthritis Rheum; 2006 Dec; 54(12):3939-44. PubMed ID: 17133607
[TBL] [Abstract][Full Text] [Related]
35. Pilot study to determine whether transient receptor potential melastatin type 8 (TRPM8) antibodies are detected in scleroderma.
Shah AA; Montagne J; Oh SY; Wigley FM; Casciola-Rosen L
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S123-6. PubMed ID: 26242276
[TBL] [Abstract][Full Text] [Related]
36. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.
Nihtyanova SI; Sari A; Harvey JC; Leslie A; Derrett-Smith EC; Fonseca C; Ong VH; Denton CP
Arthritis Rheumatol; 2020 Mar; 72(3):465-476. PubMed ID: 31682743
[TBL] [Abstract][Full Text] [Related]
37. Association of psoriasin (S100A7) with clinical manifestations of systemic sclerosis: is its presence in whole saliva a potential predictor of pulmonary involvement?
Baldini C; Giusti L; Bazzichi L; Ciregia F; Giannaccini G; Giacomelli C; Doveri M; Del Rosso M; Bombardieri S; Lucacchini A
J Rheumatol; 2008 Sep; 35(9):1820-4. PubMed ID: 18634149
[TBL] [Abstract][Full Text] [Related]
38. Anti-PM/Scl autoantibodies in patients without clinical polymyositis or scleroderma.
Schnitz W; Taylor-Albert E; Targoff IN; Reichlin M; Scofield RH
J Rheumatol; 1996 Oct; 23(10):1729-33. PubMed ID: 8895149
[TBL] [Abstract][Full Text] [Related]
39. Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes.
Clark KEN; Campochiaro C; Host LV; Sari A; Harvey J; Denton CP; Ong VH
Sci Rep; 2022 Jul; 12(1):11212. PubMed ID: 35780179
[TBL] [Abstract][Full Text] [Related]
40. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
